A remarkable invention has surfaced this week disclosed in issued US patent 10,688,191 for a chemically linked cannabinoid and chemotherapy agent. As the chemotherapy agent breaches the blood-brain barrier, the linked cannabinoid is able to act on the endocannabinoid receptors to alleviate some of the side effects of the chemotherapy agent.
Patent ‘191 specifically mentions the use of tetrahydrocannabivarin (THCV) and Carmustine as the cannabinoid and chemotherapy agent, respectively. THCV is a homologue molecule of THC and produces different side effects from THC. Cannabis site Leafly states that the common effects of THCV include appetite suppressant, stimulating bone growth as well as possibly helping with Alzheimer’s disease, diabetes, and reducing panic attacks.
HR BIOMED LLC, a Goshen, OH based company, is the assignee for patent ‘191 and appears to be operating in stealth mode at the moment. Check out Magic Number’s Cannabis Patent Forecast® to stay up to date with the cannabis industry’s vast set of intellectual property.
